Skip to main content
KPC PHARMACEUTICALS, INC. logo

KPC PHARMACEUTICALS, INC. — Investor Relations & Filings

Ticker · 600422 ISIN · CNE0000015P8 LEI · 3003007ZALHXKUFMKN96 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 2,727 across all filing types
Latest filing 2022-03-18 Audit Report / Informat…
Country CN China
Listing Shanghai Stock Exchange 600422

About KPC PHARMACEUTICALS, INC.

https://en.kpc.com.cn/

KPC Pharmaceuticals, Inc. specializes in the research, development, and manufacturing of pharmaceutical products, with a significant focus on natural and botanical medicines. The company is a global leader in the production of artemisinin-based anti-malarial treatments, including artemether and its derivatives. Its portfolio encompasses a wide range of therapeutic areas, notably cardiovascular and cerebrovascular health, where it utilizes Panax notoginseng saponins as a core component. KPC integrates traditional medicinal knowledge with modern pharmacological techniques to develop standardized botanical extracts and chemical drugs. The organization operates extensive production facilities and research centers dedicated to drug discovery and quality control. Its business activities extend to the distribution of healthcare products and the provision of medical services, aiming to provide comprehensive health solutions through innovation in natural medicine and biotechnology.

Recent filings

Filing Released Lang Actions
昆药集团2021年度审计与风险控制委员会履职报告
Audit Report / Information Classification · 95% confidence The document is titled as the "2021年度审计与风险控制委员会履职报告" which translates to the "2021 Annual Audit and Risk Control Committee Performance Report". It details the activities, meetings, and evaluations of the Audit and Risk Control Committee for the year 2021. The content focuses on the committee's oversight of audit work, internal controls, and risk management, including communication with external auditors and review of financial reports. It does not contain the full annual report or financial statements but is a standalone report on audit committee activities and their assessment of audit and internal control processes. This fits the definition of an Audit Report / Information (AR) as it is a standalone audit-related report, not the full Annual Report (10-K) or other types of filings. The document length is under 5,000 characters, but it is a substantive report, not merely an announcement or certification, so it is not RPA or RNS. Therefore, the correct classification is AR with high confidence. FY 2021
2022-03-18 Chinese
东海证券股份有限公司关于昆药集团股份有限公司2021年度募集资金存放与实际使用情况专项核查意见
Regulatory Filings
2022-03-18 Chinese
昆药集团2021年年度报告摘要
Annual Report Classification · 100% confidence The document is titled as the 2021 annual report summary of Kunming Pharmaceutical Group Co., Ltd. It contains detailed financial data for the year 2021, including total assets, net profit, revenue, quarterly financial data, shareholder information, business overview, industry analysis, and company strategy. The text references the full annual report and audit opinions, and includes comprehensive financial and operational information typical of an annual report. The length of the document (15,000 characters) and the depth of financial and business details confirm it is the actual annual report, not just an announcement or summary. Therefore, the document fits the definition of an Annual Report (10-K). FY 2021
2022-03-18 Chinese
昆药集团2021年独立董事述职报告
Board/Management Information Classification · 95% confidence The document is titled as the "2021 Independent Directors' Work Report" of Kunming Pharmaceutical Corporation. It details the independent directors' qualifications, attendance at board and shareholder meetings, their opinions on related party transactions, external guarantees, fundraising usage, board nominations, senior management appointments, remuneration, equity incentives, auditor appointments, dividend payments, information disclosure, and internal control execution for the year 2021. The content is a comprehensive report on the independent directors' duties and oversight activities during the fiscal year, which aligns with a management or governance report rather than a full annual report or audit report. It is not a short announcement or certification but a substantive report on governance and management oversight. Therefore, the document fits best under the category of Board/Management Information (MANG), as it focuses on board activities, director duties, and governance oversight.
2022-03-18 Chinese
关于昆药集团股份有限公司非经营性资金占用及其他关联资金往来情况汇总表的专项审核报告
Regulatory Filings
2022-03-18 Chinese
昆药集团2021年度审计报告
Regulatory Filings
2022-03-18 Chinese

Browse filings by year

26 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.